In-Vivo and Ex-Vivo Brain Uptake Studies of Peptidomimetic Neurolysin Activators in Healthy and Stroke Animals
Purpose Neurolysin (Nln) is a peptidase that functions to preserve the brain following ischemic stroke by hydrolyzing various neuropeptides. Nln activation has emerged as an attractive drug discovery target for treatment of ischemic stroke. Among first-in-class peptidomimetic Nln activators, we selected three lead compounds (9d, 10c, 11a) for quantitative pharmacokinetic analysis to provide valuable information for subsequent preclinical development. Methods Pharmacokinetic profile of these compounds was studied in healthy and ischemic stroke-induced mice after bolus intravenous administration. Brain concentration and brain uptake clearance ($ K_{in} $) was calculated from single time point analysis. The inter-relationship between LogP with in-vitro and in-vivo permeability was studied to determine CNS penetration. Brain slice uptake method was used to study tissue binding, whereas P-gp-mediated transport was evaluated to understand the potential brain efflux of these compounds. Results According to calculated parameters, all three compounds showed a detectable amount in the brain after intravenous administration at 4 mg/kg; however, 11a had the highest brain concentration and brain uptake clearance. A strong correlation was documented between in-vitro and in-vivo permeability data. The efflux ratio of 10c was ~6-fold higher compared to 11a and correlated well with its lower $ K_{in} $ value. In experimental stroke animals, the $ K_{in} $ of 11a was significantly higher in ischemic vs. contralateral and intact hemispheres, though it remained below its $ A_{50} $ value required to activate Nln. Conclusions Collectively, these preclinical pharmacokinetic studies reveal promising BBB permeability of 11a and indicate that it can serve as an excellent lead for developing improved drug-like Nln activators..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Pharmaceutical research - 39(2022), 7 vom: 03. März, Seite 1587-1598 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nozohouri, Saeideh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s11095-022-03218-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079052772 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079052772 | ||
| 003 | DE-627 | ||
| 005 | 20230508192449.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-022-03218-w |2 doi | |
| 035 | |a (DE-627)OLC2079052772 | ||
| 035 | |a (DE-He213)s11095-022-03218-w-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Nozohouri, Saeideh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-Vivo and Ex-Vivo Brain Uptake Studies of Peptidomimetic Neurolysin Activators in Healthy and Stroke Animals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Purpose Neurolysin (Nln) is a peptidase that functions to preserve the brain following ischemic stroke by hydrolyzing various neuropeptides. Nln activation has emerged as an attractive drug discovery target for treatment of ischemic stroke. Among first-in-class peptidomimetic Nln activators, we selected three lead compounds (9d, 10c, 11a) for quantitative pharmacokinetic analysis to provide valuable information for subsequent preclinical development. Methods Pharmacokinetic profile of these compounds was studied in healthy and ischemic stroke-induced mice after bolus intravenous administration. Brain concentration and brain uptake clearance ($ K_{in} $) was calculated from single time point analysis. The inter-relationship between LogP with in-vitro and in-vivo permeability was studied to determine CNS penetration. Brain slice uptake method was used to study tissue binding, whereas P-gp-mediated transport was evaluated to understand the potential brain efflux of these compounds. Results According to calculated parameters, all three compounds showed a detectable amount in the brain after intravenous administration at 4 mg/kg; however, 11a had the highest brain concentration and brain uptake clearance. A strong correlation was documented between in-vitro and in-vivo permeability data. The efflux ratio of 10c was ~6-fold higher compared to 11a and correlated well with its lower $ K_{in} $ value. In experimental stroke animals, the $ K_{in} $ of 11a was significantly higher in ischemic vs. contralateral and intact hemispheres, though it remained below its $ A_{50} $ value required to activate Nln. Conclusions Collectively, these preclinical pharmacokinetic studies reveal promising BBB permeability of 11a and indicate that it can serve as an excellent lead for developing improved drug-like Nln activators. | ||
| 700 | 1 | |a Esfahani, Shiva Hadi |4 aut | |
| 700 | 1 | |a Noorani, Behnam |4 aut | |
| 700 | 1 | |a Patel, Dhaval |4 aut | |
| 700 | 1 | |a Villalba, Heidi |4 aut | |
| 700 | 1 | |a Ghanwatkar, Yashwardhan |4 aut | |
| 700 | 1 | |a Rahman, Md. Shafikur |4 aut | |
| 700 | 1 | |a Zhang, Yong |4 aut | |
| 700 | 1 | |a Bickel, Ulrich |4 aut | |
| 700 | 1 | |a Trippier, Paul C. |4 aut | |
| 700 | 1 | |a Karamyan, Vardan T. |4 aut | |
| 700 | 1 | |a Abbruscato, Thomas J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d Springer US, 1983 |g 39(2022), 7 vom: 03. März, Seite 1587-1598 |w (DE-627)130652571 |w (DE-600)843063-9 |w (DE-576)016203372 |x 0724-8741 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:7 |g day:03 |g month:03 |g pages:1587-1598 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11095-022-03218-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_2005 | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 7 |b 03 |c 03 |h 1587-1598 | ||